Author details

Full Name

Rino Rappuoli

Affiliation

ORCID

Career Start Year

1981

Papers

775

H Index

121

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36977711	mRNA vaccines and hybrid immunity use different B cell germlines against Omicron BA.4 and BA.5.		2023
37670042	A next-generation GMMA-based vaccine candidate to fight shigellosis.		2023
37655342	High-throughput bactericidal assays for monoclonal antibody screening against antimicrobial resistant .		2023
37819998	Prior SARS-CoV-2 Infection Enhances Initial mRNA Vaccine Response with a Lower Impact on Long-Term Immunity.		2023
36911719	New-age vaccine adjuvants, their development, and future perspective.	Front Immunol	2023
37080423	Historical Advances in Structural and Molecular Biology and How They Impacted Vaccine Development.		2023
37137805	Emerging roles of SARS-CoV-2 Spike-ACE2 in immune evasion and pathogenesis.		2023
37321895	Challenges in synthesis of real-world vaccine effects on meningococcal serogroup B disease for 4CMenB vaccine post-licensure effectiveness studies: A systematic review.		2023
37258926	A Lean Reverse Vaccinology Pipeline with Publicly Available Bioinformatic Tools.		2023
36872345	Save the microbes to save the planet. A call to action of the International Union of the Microbiological Societies (IUMS).		2023
37443176	Memory-like innate response to booster vaccination with MF-59 adjuvanted influenza vaccine in children.	NPJ Vaccines	2023
36865381	Editorial: Intersection of biophysical and structural approaches in vaccine design.		2023
36857432	Vaccines for a sustainable planet.		2023
36463656	Editorial overview: Vaccines.		2023
36599850	B cell analyses after SARS-CoV-2 mRNA third vaccination reveals a hybrid immunity like antibody response.		2023
35101964	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines.	Pharmacological Reviews	2022
35773292	Rapid generation of Shigella flexneri GMMA displaying natural or new and cross-reactive O-Antigens.	npj Vaccines	2022
35581387	Immune response in COVID-19: what is next?	Cell Death Differ	2022
36297417	2D NMR Analysis as a Sensitive Tool for Evaluating the Higher-Order Structural Integrity of Monoclonal Antibody against COVID-19.	Pharmaceutics	2022
35697673	Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees.	Nature Communications	2022
36087745	Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB.	Journal of Infection	2022
36009408	Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections.	Biomedicines	2022
36140226	Monoclonal Antibodies for Bacterial Pathogens: Mechanisms of Action and Engineering Approaches for Enhanced Effector Functions.	Biomedicines	2022
35624207	Reply to: HultstrÃ¶m et al., Genetic determinants of mannose-binding lectin activity predispose to thromboembolic complications in critical COVID-19. Mannose-binding lectin genetics in COVID-19.	Nature Immunology	2022
36269939	The neutralizing response to SARS-CoV-2 Omicron variants BA.1 and BA.2 in COVID-19 patients and homologous and heterologous vaccinees.	Human Vaccines and Immunotherapeutics	2022
36131799	Production of two SARS-CoV-2 neutralizing antibodies with different potencies in .	Frontiers in Plant Science	2022
35988326	Classical- and bioconjugate vaccines: comparison of the structural properties and immunological response.		2022
35477725	Safety and serum distribution of anti-SARS-CoV-2 monoclonal antibody MAD0004J08 after intramuscular injection.	Nat Commun	2022
36056181	Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations.	Communications Biology	2022
35353544	The trillion dollar vaccine gap.	Science Translational Medicine	2022
36441135	Presentations at the UK National Immunisation Conference.	Human Vaccines and Immunotherapeutics	2022
35976993	Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccine.	Sci Transl Med	2022
36590399	A new dawn for monoclonal antibodies against antimicrobial resistant bacteria.		2022
36495000	A strategic model for developing vaccines against neglected diseases: An example of industry collaboration for sustainable development.		2022
36469761	mRNA, the beginning of a new influenza vaccine game.	Proceedings of the National Academy of Sciences of the United States of America	2022
33861374	Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action.	Current Topics in Microbiology and Immunology	2022
34914040	Challenges for Vaccinologists in the First Half of the Twenty-First Century.	Methods in Molecular Biology	2022
35029310	Innovative vaccine approaches-a Keystone Symposia report.	Ann N Y Acad Sci	2022
34417349	SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.	Proc Natl Acad Sci U S A	2021
35590160	Bacteriophages, a multi-tool to fight infectious disease.	Med	2021
33972793	SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies.	Nature Medicine	2021
34017343	Antibodies Elicited by the GMMA Vaccine in Adults Trigger Complement-Mediated Serum Bactericidal Activity: Results From a Phase 1 Dose Escalation Trial Followed by a Booster Extension.	Frontiers in Immunology	2021
33542518	The role of vaccines in combatting antimicrobial resistance.	Nature Reviews Microbiology	2021
34060329	Staphylococcal Protein A Induces Leukocyte Necrosis by Complexing with Human Immunoglobulins.	mBio	2021
33933528	Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination.	J Infect	2021
33873199	Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.	Nature	2021
33656515	Immunodominant antibody germlines in COVID-19.	Journal of Experimental Medicine	2021
33500559	Antibodies, epicenter of SARS-CoV-2 immunology.	Cell Death and Differentiation	2021
33758839	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines.	bioRxiv	2021
33594366	Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates.	bioRxiv	2021